
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is a clinical-stage biotechnology company that has a positive outlook as its lead therapeutic candidate, Revtorpyk (gedatolisib), has shown potential in targeting multiple nodes of the PI3K/AKT/mTOR pathway and overcoming adaptive resistance mechanisms. With data showing efficacy in HR+/HER2- breast cancer and ongoing trials for other solid tumors, and a successful commercial launch planned for late 3Q26, indications are that Celcuity could be a strong competitor in the market. With promising treatment duration data and solid financials, Celcuity is poised for success.
Bears say
Celcuity is expected to face declining sales as competition intensifies in the HR+/HER2- metastatic breast cancer market, and the company's high-priced drug, gedatolisib, may not be able to maintain its expected peak sales of over $2.5 billion. In addition, the company's financials show increased expenses and a high net loss, which could negatively impact investor perception of the company's prospects. Overall, the combination of competitive challenges and financial risks suggests a negative outlook for Celcuity's stock.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares